Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
Posted: 16 March 2023 Immutep Limited, a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, announced the initiation of AIPAC-003 (Active Immunotherapy, Eftilagimod Alpha, and PAClitaxel), an integrated Phase II/III trial to evaluate eftilagimod alpha (“efti”)…
Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years
Posted: 16 March 2023 Pfizer Inc. and BioNTech SE announced today that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine…
Extension for project tackling antimicrobial resistance in PNG
Posted: 15 March 2023 A major project tackling antimicrobial resistance (AMR) in Papua New Guinea has been extended until December 2023. The Fleming Fund Country Grant – Papua New Guinea (PNG) is led by Burnet Institute working in close collaboration…
Moderna Outlines Commitment to Corporate Growth and Announces U.S. Expansion in 2023
Posted: 15 March 2023 Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that it is expanding its U.S. presence and establishing a corporate presence on the West Coast with new offices in South…
Optiscan Platform Highly Accurate for Oral Cancer Diagnosis
Posted: 15 March 2023 Optiscan Imaging Limited is pleased to announce interim results of its oral imaging study conducted by Professor Farah and his team at the Australian Centre for Oral Oncology Research & Education. Data analysed as…
Back-to-back Studies Validate geneType Breast Cancer Risk Test
Posted: 14 March 2023 Genetic Technologies Limited, a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment…
FDA Approves First Treatment for Rett Syndrome
Posted: 14 March 2023 Neuren Pharmaceuticals announced that its North America partner Acadia Pharmaceuticals received US Food and Drug Administration (FDA) approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years…
Imagion Funding Update
Posted: 9 March 2023 Imagion Biosystems, a company dedicated to improving healthcare through the early detection of cancer, announced an entitlement offer to its shareholders seeking to raise up to $2.4 million as well as a funding facility…
BioCurate Secures Renewed Funding Commitments, Announces Leadership Changes
Posted: 9 March 2023 BioCurate, an independently operated joint venture between The University of Melbourne and Monash University, with support from the Victorian State Government, announced today it has secured renewed funding commitments from its shareholders, totalling $20m…
Alterity Therapeutics Enrolls First Patient in Italy in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Posted: 8 March 2023 Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant in Italy has been dosed in the Company’s Phase 2 clinical trial of ATH434 in…
Revolutionary new cholesterol drug to save lives
Posted: 7 March 2023 Hundreds of thousands of Australians with life-threatening high cholesterol are set to benefit from a revolutionary new pill following the successful research and trial by Professor Stephen Nicholls, Director of the Victorian Heart Institute and Victorian Heart…
Better detection of hepatitis B and hepatitis C will reduce the risk of cancer
Posted: 7 March 2023 Over 200,000 people in Australia live with hepatitis B and over 100,000 people with hepatitis C, and have a greater risk of liver cancer – one of the leading causes of cancer death in…
